TRILLIUM THERAPEUTICS INC's ticker is and the CUSIP is 89620X506. A total of 25 filers reported holding TRILLIUM THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $790,000 | +199.2% | 45,000 | -25.0% | 0.06% | +255.6% |
Q2 2017 | $264,000 | +187.0% | 60,013 | +269.6% | 0.02% | +100.0% |
Q4 2016 | $92,000 | -29.8% | 16,239 | +11.1% | 0.01% | -47.1% |
Q2 2016 | $131,000 | -26.4% | 14,614 | -26.1% | 0.02% | -59.5% |
Q4 2014 | $178,000 | – | 19,783 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Endurant Capital Management LP | 206,800 | $36,314,000 | 8.27% |
Fairmount Funds Management LLC | 886,281 | $15,563,000 | 5.66% |
FRAZIER MANAGEMENT LLC | 3,123,107 | $54,984,000 | 4.40% |
ACT CAPITAL MANAGEMENT, LLC | 466,000 | $8,183,000 | 4.24% |
RAMIUS ADVISORS LLC | 338,042 | $5,936,000 | 3.54% |
Western Standard LLC | 265,355 | $4,660,000 | 2.65% |
HAVENS ADVISORS LLC | 109,000 | $1,914,000 | 2.30% |
Crabel Capital Management, LLC | 423,490 | $7,436,000 | 2.29% |
S. MUOIO & CO. LLC | 160,000 | $2,810,000 | 2.16% |
Omni Partners US LLC | 2,366,824 | $41,561,000 | 2.13% |